This article needs to be updated.(January 2023) |
Date | 17 February 2021 – 13 April 2023 |
---|---|
Location | Japan |
Cause | COVID-19 pandemic in Japan |
Target | Full immunisation of people in Japan against COVID-19 |
Organised by | Ministry of Health, Labour and Welfare |
Participants | 77,098,247 people have received at least one vaccine dose (7 September 2021) 61,995,078 have been fully vaccinated (received both vaccine doses, 7 September 2021) [2] [3] |
Outcome | 81.8% of the Japanese population has received their first dose of a two-dose vaccine 80.6% has been fully vaccinated 58.8% has received a booster shot |
Website | Ministry of Health, Labour and Welfare |
COVID-19 vaccination in Japan started later than in most other major economies. [4] The country has frequently been regarded as "slow" in its vaccination efforts. [5] [6]
Japan has so far approved Pfizer–BioNTech, Moderna and Oxford–AstraZeneca for use. In early October 2021, data from the government shows that 60.9% of people have had their second dose, while 71.3% have received first shot. [7] Today, 79 percent of Japanese people have received two doses of a COVID-19 vaccine; 20 percent have received a third (booster) dose. [8]
On 14 February 2021, Pfizer was approved by the government of Japan, [9] and was deployed on 17 February 2021. [10] On 28 May 2021, Pfizer was approved by the Japanese health ministry panel for adolescents aged between 12 and 15 years. [11]
On 21 May 2021, Moderna and Astrazeneca were approved by the government of Japan. [12]
Vaccine | Approval | Deployment | Doses secured (million) [13] |
---|---|---|---|
Pfizer–BioNTech | 14 February 2021 | 17 February 2021 | 194 |
Moderna | 21 May 2021 [12] | 23 May 2021 [14] | 100 [15] [16] |
Oxford–AstraZeneca | 21 May 2021 [12] | 16 August 2021 [17] | 120 |
Janssen | 20 June 2022 [18] | No | |
Novavax | 19 April 2022 [19] | 26 May 2022 | 150 [20] |
Note: Japan has donated 1.24 million doses of AstraZeneca vaccine to Taiwan and 1 million doses to Vietnam. There are plans to send additional 2 million doses to these countries. Japan has also donated 1 million doses each to Thailand, Malaysia, Indonesia and the Philippines. [21] Japan also donates over 2 million doses of AstraZeneca Vaccine to Iran through COVAX. [22]
Vaccine | Country of origin | Type (technology) | Progress | Ref |
---|---|---|---|---|
AG0302-COVID‑19 AnGes Inc., AMED | Japan | DNA vaccine (plasmid) | Phase II–III (500) Randomized, double-blind, placebo controlled Nov 2020 –Apr 2021, Japan | [23] [24] [25] [26] |
S-268019 Shionogi | Japan | Subunit | Phase I–II (214) Randomized, double-blind, placebo-controlled, parallel-group. Dec 2020 –Jun 2022, Japan | [27] |
DS-5670 Daiichi Sankyo | Japan | RNA | Phase I–II (152) A Phase 1/2 Study to Assess the Safety, Immunogenicity and Recommended Dose of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects. Mar 2021 –Jul 2022, Japan | [28] [29] [30] |
KD-414 KM Biologics Co | Japan | Inactivated SARS‑CoV‑2 | Phase I–II (210) Randomized, double blind, placebo control, parallel group. Mar 2021 – Dec 2022, Japan | [31] [32] |
EXG-5003 Elixirgen Therapeutics, Fujita Health University | Japan, United States | RNA | Phase I–II (60) First in Human, randomized, placebo-controlled. Apr 2021 –Jan 2023, Japan | [33] |
This section needs expansion. You can help by adding to it. (January 2022) |
In April 2021, prime minister Suga Yoshihide announced that Japan will receive 50 million doses of the Pfizer vaccine after a meeting with the company's CEO. [4] [34]
The roll out of the vaccines in Japan, with 4 percent of the population inoculated as of May 21, 2021, has led to criticisms of slow approval, disruptions on import, and the lack of medical professionals. [35] [36] A poll conducted in April showed that more than 60 percent of people were dissatisfied with Japan's vaccine rollout, with experts stating that it was too late now to stop the spread of variants with vaccines. [37]
On May 21, 2021, several municipal governments in Kanagawa Prefecture were getting rid of their Moderna vaccine stocks as the doses are near their expiry date. [38] On June 5, 2022, around 740,000 Moderna doses will be disposed of due to being expired. [39]
This section is empty. You can help by adding to it. (May 2021) |
This section is empty. You can help by adding to it. (May 2021) |
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19. Developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose, and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant, and 61% against the Delta variant.
COVID-19 vaccination in Switzerland is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination campaign in Italy is a mass immunization campaign that was put in place by the Italian government in order to respond to the ongoing COVID-19 pandemic. It started on 27 December 2020, together with most countries in the European Union.
The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, with the goal of vaccinating all willing people in Australia before 2022. Front-line workers and aged care staff and residents had priority for being inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine was not included in the Australian vaccination program as of June 2021.
COVID-19 vaccination in Canada is an ongoing, intergovernmental effort coordinated between the bodies responsible in the Government of Canada to acquire and distribute vaccines to individual provincial and territorial governments who in turn administer authorized COVID-19 vaccines during the COVID-19 pandemic in Canada. Provinces have worked with local municipal governments, hospital systems, family doctors and independently owned pharmacies to aid in part, or in full with vaccination rollout. The vaccination effort in full is the largest such immunization effort in the nation's history. The vaccination effort began December 14, 2020, and is currently ongoing.
COVID-19 vaccination in South Africa is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination programs have begun in many countries and territories in Africa. In June 2021, the World Health Organization predicted that 47 of Africa's 54 nations would fall short of the aim of vaccinating 10% of their people by September 2021. In June, Africa accounted for fewer than 1% of worldwide vaccine doses delivered. Africa received in total less than 2% of the 3 billion vaccination doses provided globally.
The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.
COVID-19 vaccination in South Korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks third in Asia and fifth in the world.
Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.
Nepal began administration of COVID-19 vaccines on 27 January 2021. 1 million Oxford-Astrazeneca vaccines were provided by India as a grant while Nepal brought 2 million doses from Serum Institute of India (SII) and was one of the first to receive COVID-19 vaccines. The delivery of the first 1 million doses arrived on 21 February. In March, India's decision to ban exports of vaccines created uncertainty over whether Nepal would be able to continue its vaccinations. By April, SII had only provided half of the 2 million doses for which Nepal had paid in full. A spokesperson for the Indian Ministry of External Affairs rejected the notion of an export ban and said "We will export vaccines taking into account the domestic demand." By late July, there was still uncertainty in Nepal over when SII would deliver the vaccines that were purchased, although Prime Minister Narendra Modi said India would "resume the supply of vaccines soon."
COVID-19 vaccination in Iceland is an effort to immunize the adult population of Iceland due to the COVID-19 pandemic. As of July 2021, more than 260,000 individuals had received at least one dose of COVID-19 vaccine, which was over 78% of the country's population. On November 21, 2021, 90% of the target population had been fully vaccinated, while around 1 in 5 people had received a booster on top of that; by December 9, 2021, the share of the population having received a booster shot exceeded 50%. On December 13, 2021, the country began offering Pfizer vaccinations to children aged 5–11.
COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. The United States donated over 1.5 million Moderna vaccine through COVAX.
COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country.
The COVID-19 vaccination in the United Arab Emirates is an ongoing mass immunization campaign, in response to the ongoing pandemic.
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness, and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:
COVID-19 vaccination in Ontario began in December 2020, when the first doses of the Pfizer vaccine were administered. In February 2021, shipments for both the Pfizer and Moderna vaccines increased significantly. By May 2021, over 50 percent of Ontarians had received their first dose. By the beginning of 2022, over 80 percent of Ontarians had received their first dose.